Introduction
CiMaas develops immunotherapy for cancer by optimally engaging the immune system.
Read more about CiMaas Immunotherapy products,
or watch our video.
Collaboration for the discovery and development of innovative cancer-specific CAR-NK products is underway, leveraging Combotope Therapeutics' proprietary Tumor Glycoform specific scFv discovery platform and CiMaas's Adoptive CAR-NK technology.
- CiMaas has the option to develop and commercialize up to three therapeutic candidates.
- Combotope Therapeutics will receive upfront payment, success fees, and royalties on sales.
- First candidate Mucin-1 tumor glycoform nominated.
CiMaas filed patent application on feeder cell preparation in support of its NK cell therapy program
CiMaas has filed a new patent application on a new method for the feeder cell preparation in support of its NK cell therapy program. Treatment with Natural Killer (NK) cells is the CiMaas strategy to potentially cure patients with cancer. CiMaas uses a feeder cell based NK cell expansion protocol to generate high NK cell numbers under GMP.
CiMaas has created a master cell and working cell bank of its feeder cell line to expand NK cells with maximum proliferation
CiMaas BV announces that it has created a GMP grade master cell bank of the F012 feeder cell line to support Natural Killer (NK) cell expansion isolated from peripheral blood cells. CiMaas had generated a feeder cell line containing two genes that induce NK cell proliferation and maturation resulting in NK cells with a memory phenotype and high killing capacity.